This article has Open Peer Review reports available.
Extramammary Paget’s disease affecting the external auditory canal: a case report
© Bomfim et al.; licensee BioMed Central Ltd. 2013
Received: 28 April 2013
Accepted: 26 September 2013
Published: 7 November 2013
Extramammary Paget’s disease is a rare histological type of intraepithelial adenocarcinoma that mainly affects apocrine sweat gland-rich areas. Predilection sites include the anogenital region and, less commonly, the axillae. These tumors rarely occur in non-apocrine regions. The aim of this case report is to describe a case of extramammary Paget’s disease in the external auditory canal with extensive temporal bone involvement and skull base invasion.
A 40-year-old Caucasian man presented with a progressively growing, vegetating lesion localized in his right-hand external auditory canal. He had peripheral facial nerve paralysis and complete ipsilateral hearing loss. An incisional biopsy suggested extramammary Paget’s disease, and the immunohistochemical analysis confirmed the diagnosis. The tumor was considered inoperable because of the extensive skull base involvement, and he was referred for palliative radiotherapy.
We report here the third case of extramammary Paget’s disease affecting the external auditory canal to be described in the literature. In all the three cases, the prognosis was unfavorable despite treatment.
KeywordsExternal auditory canal External ear Extramammary Head-neck tumors Paget’s disease
Extramammary Paget’s disease (EMPD) is a rare histological type of intraepithelial adenocarcinoma that mainly affects apocrine sweat gland-rich areas. The predilection sites include the anogenital region and, less commonly, the axillae. These tumors rarely occur in non-apocrine regions. Despite the presence of modified ceruminous sweat glands in the external auditory canal, there have been only two previously reported cases of EMPD in this region[2, 3]. The aim of this case report is to describe the case of a patient with EMPD in the external auditory canal, with extensive temporal bone involvement and skull base invasion. The patient had a good initial response to radiotherapy but developed a lung metastasis and died 4 months after the end of treatment.
Focally positive (++)
The tumor was considered inoperable because of the extensive skull base involvement, and the patient was referred for palliative radiotherapy. The patient underwent 36 sessions of radiotherapy and was given a total radiation dose of 72Gy. A complete response was achieved at the primary site, but during treatment, diffuse bilateral pulmonary metastases were detected. The patient experienced significant weight loss during treatment and died 4 months after completing radiotherapy.
EMPD was first reported by Crocker in 1889 and is a rare type of adenocarcinoma of the apocrine sweat glands with intraepithelial extension that primarily affects sites with high densities of these glands, such as the genital, perianal, and axillary regions. Other sites are quite rarely affected; these include the external auditory canal[2, 3], upper eyelid (glands of Moll), and umbilical region, where there is evidence of modified apocrine glands. In addition, EMPD can occur in places with no evidence of apocrine glands, such as the face. In such cases, EMPD is described as ectopic.
In its usual presentation in the genital and perianal regions, EMPD is reported as a slow-growing, erythematous, and well-demarcated lesion that forms crusts, scaly edges, and occasional ulcerations. These tumors grow until achieving local invasion and metastasis. Precise diagnoses are often delayed for years due to nonspecific appearances. The behaviors of EMPD that have been described in the literature are very different from those observed in the present case, in which the lesion presented with rapid and aggressive growth, including lymph node metastasis within a few months, and led to the patient’s death.
Cases of EMPD that affect the external auditory canal are extremely rare. Such a case was first published by Kaneko and Fligiel in 1975 and then by Gonzalez-Castro et al. in 1998. In both cases, EMPD was very aggressive, and the patients died within months of the diagnoses, despite treatment. The case described here is the third reported case. Adenocarcinomas that arise from the ceruminous glands of the external auditory canal are rare malignancies that usually present as growing and painful masses in the external auditory canals of middle-aged patients. Besides ear pain and rapid tumor growth, the most common symptoms include hearing impairments such as hearing loss, deafness and tinnitus, discharge, infection, bleeding, facial nerve paralysis, paresthesia, dizziness, and balance disorders.
Immunohistochemistry is critical for diagnosis because the histological aspect can resemble amelanotic melanoma or pagetoid Bowen’s disease. Markers such as CEA and low-molecular-weight cytokeratins, including PKK1, CK7, GR53, and 35 Beta H11, are often positive in Paget’s cells and apocrine sweat glands. In 2009, Plaza et al. published a study on a series of 47 patients with EMPD, in which more than 30% expressed the Her2 (Neu) receptor. These cases were associated with potentially more aggressive lesions and had higher rates of recurrence after treatment. The patient in the present case had tumor cells positive for CEA, CK7, Her2 (Neu), and GCDFP-15.
Combined surgical resection and adjuvant radiotherapy provides the most effective treatment; however, several series showed good results with radiotherapy alone in inoperable cases. For metastatic EMPD, most authors have recommended combinations of multiple chemotherapy drugs such as 5-fluorouracil, mitomycin C, vincristine, cisplatin, and epirubicin in combination with radiotherapy. However, the serious adverse effects of these treatment regimens should be taken into account. The detection of Her2 (Neu) in a subgroup of patients with EMPD could provide a new starting point for immunotherapy in a manner similar to therapy for Her2 (Neu)-positive breast cancer patients[13, 14].
The prognosis of EMPD in its usual presentation is generally favorable and depends on the extent of the lesion, depth of invasion, and lymph node spread. The associated mortality rate ranges from 13% to 18%, and the survival rate at 5 years is 72%.
In summary, EMPD very rarely affects the external auditory canal, and only two cases have been previously described in the literature. In this case and the two previous cases, the prognosis was unfavorable despite treatment. If the patient had sought medical attention earlier, the disease could possibly have been diagnosed at an initial stage and treated with radical surgery combined with adjuvant radiotherapy and could possibly have been healed.
Written informed consent was obtained from the patient’s next of kin for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Pang J, Assaad D, Breen D, Fialkov J, Antonyshyn O, Balogh J, Tsao M, Kamra J, Czarnota G, Barnes EA: Extramammary Paget disease: review of patients seen in a non-melanoma skin cancer clinic. Curr Oncol (Toronto, Ont). 2010, 17: 43-45.Google Scholar
- Gonzalez-Castro J, Iranzo P, Palou J, Mascaro JM: Extramammary Paget's disease involving the external ear. Brit J Dermatol. 1998, 138: 914-915. 10.1046/j.1365-2133.1998.02243.x.View ArticleGoogle Scholar
- Fligiel Z, Kaneko M: Extramammary Paget's disease of the external ear canal in association with ceruminous gland carcinoma. A case report. Cancer. 1975, 36: 1072-1076. 10.1002/1097-0142(197509)36:3<1072::AID-CNCR2820360334>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Crocker HR: Paget’s disease affecting the scrotum and penis. Trans Pathol Soc Lond. 1889, 40: 187-191.Google Scholar
- Cohen MA, Hanly A, Poulos E, Goldstein GD: Extramammary Paget's disease presenting on the face. Dermatol Surg. 2004, 30: 1361-1363. 10.1111/j.1524-4725.2004.30412.x.PubMedGoogle Scholar
- Knauer WJ, Whorton CM: Extramammary Paget's disease originating in Moll's glands of the lids. Transactions - Am Acad Ophthalmol Otolaryngol. 1963, 67: 829-833.Google Scholar
- Remond B, Aractingi S, Blanc F, Verola O, Vignon D, Dubertret L: Umbilical Paget's disease and prostatic carcinoma. Brit J Dermatol. 1993, 128: 448-450. 10.1111/j.1365-2133.1993.tb00208.x.View ArticleGoogle Scholar
- Chilukuri S, Page R, Reed JA, Friedman J, Orengo I: Ectopic extramammary Paget's disease arising on the cheek. Dermatol Surg. 2002, 28: 430-433. 10.1046/j.1524-4725.2002.01199.x.PubMedGoogle Scholar
- Zollo JD, Zeitouni NC: The Roswell Park Cancer Institute experience with extramammary Paget's disease. British J Dermatol. 2000, 142: 59-65. 10.1046/j.1365-2133.2000.03242.x.View ArticleGoogle Scholar
- Siesling S, Elferink MA, van Dijck JA, Pierie JP, Blokx WA: Epidemiology and treatment of extramammary Paget disease in the Netherlands. Eur J Surg Oncol. 2007, 33: 951-955. 10.1016/j.ejso.2006.11.028.View ArticlePubMedGoogle Scholar
- Crain N, Nelson BL, Barnes EL, Thompson LD: Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases. Head Neck Pathol. 2009, 3: 1-17. 10.1007/s12105-008-0095-9.View ArticlePubMedGoogle Scholar
- Thompson LD, Nelson BL, Barnes EL: Ceruminous adenomas: a clinicopathologic study of 41 cases with a review of the literature. Am J Surg Pathol. 2004, 28: 308-318. 10.1097/00000478-200403000-00003.View ArticlePubMedGoogle Scholar
- Wagner G, Sachse MM: Extramammary Paget disease – clinical appearance, pathogenesis, management. J German Soc Dermatol: JDDG. 2011, 9: 448-454.Google Scholar
- Plaza JA, Torres-Cabala C, Ivan D, Prieto VG: HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutaneous Pathol. 2009, 36: 729-733. 10.1111/j.1600-0560.2008.01148.x.View ArticleGoogle Scholar
- Hatta N, Yamada M, Hirano T, Fujimoto A, Morita R: Extramammary Paget's disease: treatment, prognostic factors and outcome in 76 patients. Brit J Dermatol. 2008, 158: 313-318.Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.